Pharma Focus Asia

FUJIFILM Diosynth Biotechnologies Invests US$55 million for Gene Therapy Facility Expansion

Introduction:

FUJIFILM Diosynth Biotechnologies (FDB) has announced an investment of US$55million to establish a new Gene Therapy Innovation Center.

Features:

The new facility will be adjacent to FDB's existing cGMP gene therapy manufacturing facility in College Station, TX.

The innovation center will have a dedicated process and analytical development laboratories.

The 60,000 square feet laboratories will house state-of-the-art upstream, downstream, and analytical development technologies.

Fujifilm also announced that the additional investments in the project will expand FDB's gene therapy cGMP capacity, with new clean rooms and eight new single-use bioreactors with a capacity of 500 liters to 2,000 liters.

Moreover, the site has been providing gene therapy fill/finish services for both clinical and commercial products since early 2019.

The first stage of the manufacturing expansion is expected to be completed and will start its operations in the fall of 2021.

Specifications:

NameFUJIFILM Diosynth Biotechnologies
TypeExpansion
BudgetUS$55 million
magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024